Analysts expect OvaScience Inc. (NASDAQ:OVAS) to report $80,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for OvaScience’s earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $60,000.00. OvaScience posted sales of $120,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The company is expected to report its next quarterly earnings results on Thursday, March 1st.

On average, analysts expect that OvaScience will report full year sales of $80,000.00 for the current year, with estimates ranging from $260,000.00 to $300,000.00. For the next financial year, analysts anticipate that the company will report sales of $2.01 million per share, with estimates ranging from $220,000.00 to $5.52 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow OvaScience.

Several brokerages have recently issued reports on OVAS. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of OvaScience in a report on Monday, November 6th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Wednesday, October 4th.

Institutional investors have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. purchased a new stake in OvaScience in the first quarter valued at about $107,000. Zacks Investment Management acquired a new stake in OvaScience during the second quarter worth about $140,000. LMR Partners LLP acquired a new stake in OvaScience during the second quarter worth about $145,000. Susquehanna International Group LLP grew its holdings in OvaScience by 87.2% during the second quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 52,538 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in OvaScience by 28.8% during the second quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock worth $256,000 after acquiring an additional 36,720 shares during the period. Institutional investors own 55.27% of the company’s stock.

OvaScience (OVAS) opened at $1.46 on Tuesday. OvaScience has a twelve month low of $1.25 and a twelve month high of $3.42.

ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/05/zacks-analysts-expect-ovascience-inc-ovas-will-announce-quarterly-sales-of-80000-00.html.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get a free copy of the Zacks research report on OvaScience (OVAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.